{"disease":{"id":"breast-cancer-radiotherapy","name":"breast cancer radiotherapy"},"drugs":{"marketed":[{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, and/or prior radiotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, and/or prior surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, and/or prior hormone therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, and/or prior targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, and/or prior immunotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, and/or prior chemotherapy with a taxane","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, and/or prior chemotherapy with a platinum agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, and/or prior chemotherapy with a microtubule inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, and/or prior chemotherapy with a PARP inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, and/or prior chemotherapy with a mTOR inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, and/or prior chemotherapy with a HER2-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, and/or prior chemotherapy with a PIK3CA-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, and/or prior chemotherapy with a hormone receptor antagonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, and/or prior chemotherapy with a hormone receptor agonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, and/or prior chemotherapy with a selective estrogen receptor degrader","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, and/or prior chemotherapy with a selective estrogen receptor modulator","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, and/or prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor and/or a PIK3CA inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07469267","title":"Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases","phase":"NA","overall_status":"RECRUITING","enrollment_count":1608,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04472845","title":"HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).","phase":"NA","overall_status":"RECRUITING","enrollment_count":1018,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT04889924","title":"ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":820,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT05253170","title":"Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":622,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT05804916","title":"Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":556,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06826885","title":"Safety and Efficacy of IMPT or IMRT for Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03077191","title":"Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy: a Single Institution Experience","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":410,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT07021911","title":"Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fondazione Policlinico Universitario Campus Bio-Medico","has_results":false},{"nct_id":"NCT03878342","title":"Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":295,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT07100600","title":"Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06648148","title":"Molecular Biomarkers of Response to Radiation Therapy in Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Institute of Oncology Ljubljana","has_results":false},{"nct_id":"NCT03870919","title":"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT03761940","title":"Health Status of Women With Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03333993","title":"Mat Pilates in Women With Breast Cancer During Adjuvant Radiotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Instituto Nacional de Cancer, Brazil","has_results":false},{"nct_id":"NCT06197581","title":"Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":148,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04775290","title":"Yoga on QOL Physiological Distress&Fatigue, on Patients Affected by Breast Cancer in Adjuvant Radiotherapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT06321653","title":"Lymphedema Evaluation After Adjuvant Hypofractionated Radiotherapy for 1-2 Macrometastatic Sentinel Lymph Nodes","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT03750396","title":"Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT05591456","title":"Accelerated Hypofractionated 1 Week Radiotherapy in Breast Cancer Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Zagazig University","has_results":false},{"nct_id":"NCT05144867","title":"Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":98,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT05762900","title":"Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03801850","title":"Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: MorphoBreast3D","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Centre Paul Strauss","has_results":false},{"nct_id":"NCT06796257","title":"Monaco-Serial Biological Function K-value Index Constraint for Cardiac Dose","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Jianjun Lai","has_results":false},{"nct_id":"NCT04842409","title":"Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria Careggi","has_results":false},{"nct_id":"NCT03737500","title":"Standard Silicone-based vs. B-Lite® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Istituti Clinici Scientifici Maugeri SpA","has_results":false},{"nct_id":"NCT04059809","title":"Photobiomodulation for Breast Cancer Radiodermatitis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"AC Camargo Cancer Center","has_results":false},{"nct_id":"NCT04507789","title":"Exercise Therapy During Radiotherapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT04149522","title":"Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","has_results":false},{"nct_id":"NCT03997188","title":"Zinc-L-Carnosine Prevents Dysphagia in Breast Cancer Patients Undergoing Adjuvant Radiotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Cynthia Aristei","has_results":false},{"nct_id":"NCT05992870","title":"Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Hubei Cancer Hospital","has_results":false},{"nct_id":"NCT04913532","title":"Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT05673304","title":"Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06070155","title":"Effect of Aerobic Exercises on Trace Elements in Post-menopausal Women After Radiotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT07023796","title":"Autologous Fat Infiltration Versus General Measures as Treatment in Radiodermatitis Induced for Radiotherapy in Breast Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Instituto Mexicano del Seguro Social","has_results":false},{"nct_id":"NCT04509284","title":"Analgesic Effect of Resistance Training for Breast Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Aalborg University","has_results":false},{"nct_id":"NCT05726604","title":"4D CT Scan Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Central Hospital Saint Quentin","has_results":false},{"nct_id":"NCT04535895","title":"Simultaneous Integrated Boost Technique in Breast Cancer Radiotherapy","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Medical University of Graz","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}